Array Biopharma (ARRY) Tops Q2 EPS by 12c; CFO Resigns; Updates on Novartis Agreement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. NKE
9. MU
10. AWK

Go back to Array Biopharma (ARRY) Tops Q2 EPS by 12c; CFO Resigns; Updates on Novartis Agreement

Array BioPharma (ARRY) PT Lifted to $15 at Piper Jaffray; Proforma Cash Of $222 Million To File NDAs

February 4, 2015 9:16 AM EST

Piper Jaffray analyst Edward Tenthoff boosted his price target on Overweight-rated Array BioPharma (NASDAQ: ARRY) to $15.00 (from $9.00) with the company ending Q2 with proforma cash of $222M to file NDAs.

Tenthoff commented, "Array ended FY2Q:15 with $142 million in cash. Including the... More